“Minneapolis, MN - The long-awaited US trial of the CoreValve transcatheter aortic-valve system is set to begin soon now that the FDA has granted Medtronic an investigational device exemption (IDE) for the pivotal study.”

“The study, which the company expects to begin by the end of the fall, will be conducted at 40 US clinical sites and led by surgeon Dr David Adams (Mount Sinai Medical Center, New York) and interventionalist Dr Jeffrey Popma (Beth Israel Deaconess Medical Center, Boston, MA).”